To hear about similar clinical trials, please enter your email below
Trial Title:
Study of Serum Tumor Markers of HBV Associated HCC
NCT ID:
NCT05825196
Condition:
HCC
Conditions: Keywords:
HBV related HCC
Study type:
Observational
Overall status:
Not yet recruiting
Study design:
Time perspective:
Other
Intervention:
Intervention type:
Diagnostic Test
Intervention name:
tumor tissue and blood tests
Description:
In this study, we need to collect an extra tube of blood for routine testing and the
tissue after completion of pathological examination.
Arm group label:
HBV-associated HCC group
Arm group label:
Healthy control group
Arm group label:
negative control group
Summary:
In this study, the investigators will detect the expression of four potential HBV-related
HCC biomarkers: PGIR,FAM3C,LAMB1 and SDC4 in tumor tissues and peripheral blood, to
explore the specific molecular markers for the early diagnosis of HBV-related HCC.
Detailed description:
Paired hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) and adjacent liver
tissues were selected, and the mRNA and protein expressions of the PGIR,FAM3C,LAMB1 and
SDC4 biomarkers in tissues were detected by RT-PCR, western Blot and immunohistochemical
analysis. At the same time, healthy subjects were selected as the control group, and mRNA
and protein expression levels of the above molecules in blood were detected by RT-PCR and
ELISA. At the same time, the correlation between the above biomarkers and the clinical
data of patients, such as diagnosis, pathological grading, recurrence, metastasis and
survival time was statistically analyzed.
Criteria for eligibility:
Study pop:
the patients admitted to the First Affiliated Hospital of Shandong First Medical
University
Sampling method:
Probability Sample
Criteria:
Inclusion Criteria:
- No local or systemic treatment was performed before surgery. The patients were
finally diagnosed with HBV-related HCC by examination and imaging examination, and
the clinicopathologic data were complete.
Exclusion Criteria:
- Patients with benign liver diseases, such as hepatic cysts and hepatic hemangiomas,
or have tumors other than HBV-related HCC.
Gender:
All
Minimum age:
18 Years
Maximum age:
80 Years
Healthy volunteers:
Accepts Healthy Volunteers
Start date:
May 1, 2023
Completion date:
December 31, 2025
Lead sponsor:
Agency:
Qianfoshan Hospital
Agency class:
Other
Source:
Qianfoshan Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05825196
